Roche invests $2.4B in autonomous AI lab with Phase III success rate at 80%

This major investment in autonomous AI could significantly accelerate drug development and improve clinical trial efficiency.

Auto-scored: Event is a positive financial and scientific development in AI for medicine with no indicated risks or misuse.